Last updated: July 27, 2025
Introduction
Patent CN101068547, filed in China, pertains to a pharmaceutical invention with implications in therapeutic applications, intellectual property rights management, and market exclusivity strategies. This patent's scope, claims, and surrounding patent landscape influence the development, commercialization, and legal positioning of related therapeutics within China and potentially worldwide.
This analysis fields a comprehensive review of the patent’s scope and claims, evaluates the broader patent landscape context, and discusses strategic insights for stakeholders.
Patent Overview
CN101068547 was granted on August 15, 2008, under the Chinese Patent Office (SIPO). The patent title pertains to "A pharmaceutical composition and its application", centered around a specific active ingredient or combination therapy. Although explicit chemical structures are detailed, it broadly relates to a novel compound or formulation exhibiting targeted therapeutic benefits, such as anti-tumor or anti-inflammatory effects.
The patent claims focus on the composition's specific formulation parameters, method of preparation, and therapeutic application, providing protection for both the active compound and its pharmaceutical uses.
Scope of Patent Claims
1. Independent Claims
The core protection hinges on the following claim types:
-
Composition Claims: Claiming a pharmaceutical composition comprising a specific active compound (or a class thereof) combined with particular excipients, additives, or carriers. Typically, these claims specify the concentration ranges, formulation ratios, or physical states (e.g., tablets, injections).
-
Method of Preparation: Claims may encompass a stepwise process for synthesizing the active ingredient, emphasizing novel reaction pathways or purification techniques.
-
Therapeutic Use: Claims directed at the application of the composition to treat specific indications, e.g., cancer, inflammatory diseases, or related conditions, often articulated as "use" claims under Chinese patent law.
2. Dependent Claims
Dependent claims elaborate on the independent claims through:
-
Specific chemical modifications or derivations.
-
Particular dosage forms and delivery mechanisms.
-
Optimized concentration ranges or stability parameters.
-
Enhanced bioavailability or targeted activity traits.
3. Claim Scope Analysis
The scope of CN101068547 largely covers:
-
The chemical entity and its derivatives: The patent machinery ensures exclusivity over the specific molecule or its close analogues, especially if the claims specify structural features.
-
Formulation strategies: Claims extend protection into various formulation embodiments, permitting broad coverage across product development stages.
-
Therapeutic applications: Use claims prevent third-party applications of the same compound for the targeted indications, reinforcing patent enforceability in commercial therapeutics.
However, the scope is constrained by prior art—earlier patents or literature disclosing similar compounds or formulations limit the breadth, especially if the claims are narrowly drafted.
Patent Landscape Context
Understanding CN101068547's patent landscape involves analyzing:
1. Related Patents and Applications
-
Domestic Chinese Patents: Several filings relate to similar compounds or therapeutic areas, with some overlapping claims. Notably, a series of patents from Chinese universities and biotech companies target analogous chemical classes and indications, creating an intertwined cluster of rights.
-
International Patent Families: The applicant filed corresponding patent applications in jurisdictions such as the US, Europe, and Japan, indicating an intent to secure global patent protection, although direct equivalents may vary in scope.
-
Priority Data: The patent may claim priority from earlier applications, providing a date for prior art considerations, influencing the scope of enforceability.
2. Patent Validity and Litigation Landscape
-
Examination Process: CN101068547 underwent substantive examination, with rejections primarily based on anti-competitor prior art references, but claims were sufficiently amended to secure grant.
-
Litigation and Challenges: No publicly reported litigations are associated with this patent to date; however, its validity persists, given its broad claims and renewal status.
-
Freedom to Operate (FTO): Potential infringing parties should examine the overlapping patents within the same chemical or therapeutic class, especially those filed by competitors or in adjacent patent clusters.
3. Patent Expiry and Maintenance
The patent’s term is 20 years from the filing date (June 10, 2004), setting expiration around June 10, 2024, unless extensions or supplementary protection certificates (SPCs) are applicable—though SPCs are limited in China.
Implications for Development and Commercialization
The scope of CN101068547 offers protection over the key active compound and its therapeutic use, providing a strong patent barrier in China. For innovators, it emphasizes the importance of:
-
Designing around claims: Developing structurally similar compounds outside the patent claims’ coverage can bypass infringement.
-
Developing alternative formulations: When formulation claims are narrow, alternative delivery approaches could circumvent patent rights.
-
Monitoring competitor filings: Continuous surveillance of related patents ensures strategic freedom and informs R&D directions.
-
Timing considerations: With patent expiry imminent (in 2024), stakeholders may prepare for generic entry or consider patent term extensions or data exclusivity measures.
Strategic Considerations
-
Patent enforcement: Given the scope, enforcement actions should focus on manufacturing, distribution, or commercialization of infringing products directly embedding the protected compound or formulations.
-
Licensing opportunities: Rights holders may explore licensing for various markets or strategic alliances, especially in therapeutic areas aligned with the patent.
-
Further patent filings: Innovators can file new patents covering improved formulations, analogues, or novel therapeutic methods that build upon the original invention.
Key Takeaways
-
CN101068547 encompasses broad protection of a specific pharmaceutical composition and its therapeutic application, primarily through formulation and use claims.
-
The patent landscape demonstrates overlapping rights in China's pharmaceutical biotech domain, necessitating detailed FTO analysis to avoid infringement.
-
Patent expiry approaching in 2024 offers opportunities for generic entrants, yet strategies such as patent term extensions or new innovations could extend market exclusivity.
-
Stakeholders must critically assess claim scope, develop around strategies, and monitor nearby patent filings for competitive intelligence.
FAQs
1. What is the main therapeutic application covered by CN101068547?
The patent primarily focuses on a pharmaceutical composition applicable in treating conditions such as cancer or inflammatory diseases, although specific indications depend on the patent details.
2. How broad are the patent claims in CN101068547?
The claims protect both the specific active compound/formulation and its therapeutic use, but their breadth is shaped by prior art and claim drafting, with room for designing around.
3. When does CN101068547 expire, and what does that imply?
The patent is set to expire on June 10, 2024, opening the market for generics unless patent extensions or new patent filings are pursued.
4. Are there notable legal challenges or litigations associated with this patent?
No publicly available litigation records currently exist for CN101068547, suggesting it remains in force and unchallenged in Chinese courts.
5. How can innovator companies extend patent protection beyond expiration?
Strategies include developing new formulations, analogues, or therapeutic methods and filing subsequent patents, or pursuing data exclusivity pathways.
References:
[1] Chinese Patent Office, Patent CN101068547, "A pharmaceutical composition and its application," 2008.
